Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Advent Therapeutics

Advent Therapeutics
2014 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
$300K LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of therapies for micro-orphan applications. The company develops a prenatal, neonatal and pediatric drug for orphans to cure disorder in newborn infants in the intensive care unit (ICU).

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
  • 6500 Old Carversville Road
  • Lumberville, PA 18933
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Advent Therapeutics’s full profile, request a free trial.

Advent Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 12-Sep-2016 $300K 00000 Completed Product Development
2. Seed Round 19-Aug-2015 00000 00000 Completed Product Development
1. Seed Round 11-Dec-2014 Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Advent Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Ben Franklin Technology Partner of Southeastern Pennsylvania Venture Capital Minority 000 0000 000000 0

Advent Therapeutics Executive Team (2)

Name Title Board
Seat
Contact
Info
Thomas Hofmann Ph.D Chief Scientific Advisor
David Lopez JD Co-Founder, Chief Business Officer & President